IMPROVE 2 

IPTp with dihydroartemisinin-piperaquine and single-course azithromycin for malaria, sexually transmitted and reproductive tract infections in HIV-infected pregnant women in Kenya and Malawi: a multi-centre, 3-arm placebo-controlled trial

Start and End dates: 2017 to 2020

Source of Funding: DFID/MRC/Wellcome Trust and European and Developing Countries Clinical Trials Partnership (EDCTP) ($0.8m)

This is an individual randomized Phase III placebo-controlled trial to determine if monthly intermittent preventive therapy (IPTp) with dihydroartemisinin-piperaquine, alone or combined with a single course of azithromycin on enrolment, in HIV-infected pregnant women receiving daily cotrimoxazole is safe and superior to daily cotrimoxazole alone for controlling malaria infection and sexually transmitted infections in areas with high antifolates resistance to SP and CTX in Malawi and Kenya. We recruited 1,335 women and followed them up till 1-month post-partum.